The company’s key achieved milestones include:

2008: December 2001 establishing BioGenCell, a privately held biotechnology company in the field of stem/progenitor cells and regenerative medicine located at the Laniado hospital in Netanya, Israel.

2009: Research and development of BioGenCell’s unique technology for rapid manufacturing of specific therapeutic stem/progenitor cell and its lead product of enriched endothelial progenitor cells (EnEPC) named BGC101 for the treatment of ‘No Option’ patients suffering from Critical Limb Ischemia (CLI).  Providing proof-of-concept for the technology.

2010: Proof of the safety and therapeutic effect of the BGC101TM therapy in the animal model of CLI.

2012: Establishing Clinical Partnership with the Technion affiliated Laniado Hospital Sanz Medical Center and Clinical trial application (CTA) dossier approval by the Laniado institutional review board (IRB).

2014: Granting of US Patent, US8709802, protecting composition of matter (COM) and methodology for producing blood-derived directed cell population of EnEPC.

Scientific publication of BioGenCell’s novel potential therapy for vascular diseases “A NOVEL POTENTIAL THERAPY FOR VASCULAR DISEASES- BLOOD-DERIVED SPC SPECIFICALLY ACTIVATED BY Dendritic CELLS”in the peer reviewed journal DIABETES/METABOLISM RESEARCH AND REVIEWS.

2015:  Granting of US Patent, US8956870, protecting methodology for cord blood-derived directed cell population of EnEPC.

Raising private funding for completing pre-clinical preparations and preparations for the ‘first in human’ clinical trial in ‘No option’ CLI patients.

Validation of the GMP manufacturing process and submission of BioGenCell’s CTA Dossier to the Israli Minstry of health (IL MOH).

Scientific publication in the peer reviewed journal CYTOTHERAPY and leading a workshop at the US National Institute of Standards and Technology (NIST) on the subject of Critical elements in the development of cell therapy potency assays for ischemic conditions.

BioGenCell’s CEO Dr. Yael Porat in TDExJerusalem presenting the Vision for The future of healthcare: On-demand personalized stem cell therapy (

2016: CTA Dossier approval by the IL MOH.

Initiation of EnEPC-CLI-01 Phase 1/2 Clinical trial in CLI patients begins at the Laniado hospital (

BioGenCell’s Co-PI, Dr. Galit Sivak, MD, Director of Vascular Surgery, Rabin Medical Center together with Dr. Yael Porat presenting the preliminary findings of BioGenCell’s study in the ICI Meeting on the 5th of December 2016.






    • BioGenCell receives grant from Pace University Lubin School of Business/ MIT Enterprise Forum for Israel.
      A $250,000 grant from Philanthropist Michael Dezer will provide Pace students from a variety of disciplines the opportunity to work closely with entrepreneurs from Israel while assisting their companies business development. Six student fellows will be chosen to provide research, analysis, product testing, and additional support to two Israel-based companies that have been selected to participate in the program. Through working with the partner companies, BioGenCell Ltd. and FreshBiz, not only will the students earn a stipend, but they will have the unique opportunity to closely interact with the business leadership teams, thus gaining valuable insights and real-world experience. The Pace entrepreneurship Lab implemented this initiative in association with the MIT Enterprise forum of Israel The Forum and its associated chapters in 28 countries comprise a global non-profit organization dedicated to promoting the growth and success of high-tech entrepreneurial ventures by connecting ideas, technology and people.

Development of a Stem Cell Therapy Product – Dr. Yael Porat Speaking at Pace University, NY

  • BioGenCell Raises $1mThe company was founded on the basis of research by CEO Dr. Yael Porat, formerly CTO of stem cell firm TheraVitae Company Ltd. BioGenCell’s product aims to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The product’s uniqueness is the use of autologous cells (cells derived from the patients themselves) to repair themselves. The company’s technology separates cells that have not yet undergone full cell speciation using special receptors found only in these cells. Porat said, “Cells from an adult include stem and early-stage cells. The company’s product is a mid-stage cell, which has already partly speciated, but still has some degree of flexibility.”
  • The US Presidential Commission for the Study of Bioethical Issues’ web site cites Dr. Porat’s article in the British Journal of Haematology in its list of “New Advances in Non-Embryonic Stem Cell Research”.